Hepatic granuloma

Summary

Hepatic granuloma (MONDO:0006241) is a disease. A subtype of liver and intrahepatic bile duct neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hepatic granuloma
Mondo ID	MONDO:0006241
EFO	EFO:1000291
SNOMED CT	714253009
UMLS	C0745754
MedGen	155428
Is cancer (heuristic)	no

Disease family

This is a subtype of liver and intrahepatic bile duct neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › liver and intrahepatic bile duct neoplasm › hepatic granuloma

Related subtypes (16): liver lipoma, liver hemangioma, hepatic angiomyolipoma, liver cancer, liver solitary fibrous tumor, liver leiomyoma, liver inflammatory myofibroblastic tumor, biliary tract neoplasm, solitary necrotic nodule of the liver, undifferentiated embryonal sarcoma of the liver, liver mesenchymal hamartoma, hepatocellular adenoma, inflammatory pseudotumor of the liver, fibrohistiocytic inflammatory pseudotumor of the liver, lymphoplasmacytic inflammatory pseudotumor of the liver, liver adenomatosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.